» Articles » PMID: 23710116

Resistin Regulates Pituitary Lipid Metabolism and Inflammation in Vivo and in Vitro

Overview
Publisher Wiley
Specialties Biochemistry
Pathology
Date 2013 May 28
PMID 23710116
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The adipokine resistin is an insulin-antagonizing factor that also plays a regulatory role in inflammation, immunity, food intake, and gonadal function and also regulates growth hormone (GH) secretion in rat adenopituitary cells cultures with the adipokine. Although adipose tissue is the primary source of resistin, it is also expressed in other tissues, including the pituitary. The aim of this study is to investigate the possible action of resistin on the lipid metabolism in the pituitary gland in vivo (rats in two different nutritional status, fed and fast, treated with resistin on acute and a chronic way) and in vitro (adenopituitary cell cultures treated with the adipokine). Here, by a combination of in vivo and in vitro experimental models, we demonstrated that central acute and chronic administration of resistin enhance mRNA levels of the lipid metabolic enzymes which participated on lipolysis and moreover inhibiting mRNA levels of the lipid metabolic enzymes involved in lipogenesis. Taken together, our results demonstrate for the first time that resistin has a regulatory role on lipid metabolism in the pituitary gland providing a novel insight in relation to the mechanism by which this adipokine can participate in the integrated control of lipid metabolism.

Citing Articles

Changes in Expression of the Genes for the Leptin Signaling in Hypothalamic-Pituitary Selected Areas and Endocrine Responses to Long-Term Manipulation in Body Weight and Resistin in Ewes.

Zieba D, Biernat W, Szczesna M, Kirsz K, Barc J, Misztal T Int J Mol Sci. 2020; 21(12).

PMID: 32545900 PMC: 7348850. DOI: 10.3390/ijms21124238.


Pituitary tissue-specific miR-7a-5p regulates FSH expression in rat anterior adenohypophyseal cells.

Wang C, Guo H, Han D, Yu Z, Zheng Y, Jiang H PeerJ. 2019; 7:e6458.

PMID: 30993031 PMC: 6461031. DOI: 10.7717/peerj.6458.


Increased serum resistin levels correlate with psoriasis: a meta-analysis.

Huang H, Shen E, Tang S, Tan X, Guo X, Wang Q Lipids Health Dis. 2015; 14:44.

PMID: 25980409 PMC: 4451955. DOI: 10.1186/s12944-015-0039-9.

References
1.
Holst J, Deacon C . Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia. 2005; 48(4):612-5. DOI: 10.1007/s00125-005-1705-7. View

2.
Kovacs M, Kineman R, Schally A, Zarandi M, Groot K, Frohman L . Effects of antagonists of growth hormone-releasing hormone (GHRH) on GH and insulin-like growth factor I levels in transgenic mice overexpressing the human GHRH gene, an animal model of acromegaly. Endocrinology. 1997; 138(11):4536-42. DOI: 10.1210/endo.138.11.5498. View

3.
Winder W, Hardie D . Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am J Physiol. 1996; 270(2 Pt 1):E299-304. DOI: 10.1152/ajpendo.1996.270.2.E299. View

4.
Wynne K, Stanley S, McGowan B, Bloom S . Appetite control. J Endocrinol. 2005; 184(2):291-318. DOI: 10.1677/joe.1.05866. View

5.
Nauck M, Heimesaat M, Orskov C, Holst J, Ebert R, Creutzfeldt W . Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993; 91(1):301-7. PMC: 330027. DOI: 10.1172/JCI116186. View